Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Sight Sciences ( (SGHT) ).
On August 27, 2025, Sight Sciences, Inc. announced a targeted plan to reduce operating expenses and improve cost efficiencies by reducing its workforce by 20% and delaying certain R&D projects. The plan aims to align the company’s operations for long-term growth without additional equity capital, with expected annual savings of approximately $11.9 million. The company also announced the departure of Chief Commercial Officer Matthew Link, effective August 31, 2025, with no immediate plans to fill the position. Despite these changes, Sight Sciences reaffirmed its revenue guidance for 2025 and expects a mid-single-digit decline in third-quarter surgical glaucoma revenue compared to the previous year.
The most recent analyst rating on (SGHT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.
Spark’s Take on SGHT Stock
According to Spark, TipRanks’ AI Analyst, SGHT is a Neutral.
Sight Sciences’ overall stock score is driven by strong technical momentum and positive earnings call sentiment, despite financial performance challenges. The company’s robust gross margin and liquidity position are offset by declining revenues and ongoing losses. Valuation remains a concern due to negative earnings and lack of dividends.
To see Spark’s full report on SGHT stock, click here.
More about Sight Sciences
Sight Sciences, Inc. operates in the medical device industry, focusing on developing and commercializing products for the treatment of eye diseases, specifically targeting surgical glaucoma and dry eye conditions.
Average Trading Volume: 145,679
Technical Sentiment Signal: Hold
Current Market Cap: $221.5M
Find detailed analytics on SGHT stock on TipRanks’ Stock Analysis page.